Mark Worthington's Insider Trades & SAST Disclosures
Mark Worthington's most recent trade in Athira Pharma Inc was a trade of 85,895 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark Worthington.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Athira Pharma Inc | Mark Worthington | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 85,895 | 85,895 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark Worthington | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 57,263 | 57,263 | - | - | Restricted Stock Units | |
| Athira Pharma Inc | Mark Worthington | General Counsel and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 36,667 | 73,333 | - | - | Restricted Stock Units | |
| Athira Pharma Inc | Mark Worthington | General Counsel and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 36,667 | 92,245 | - | 0 | Common Stock | |
| Athira Pharma Inc | Mark Worthington | General Counsel and CCO | Sale of securities on an exchange or to another person at price $ 0.56 per share. | 31 Dec 2024 | 8,510 | 83,735 | - | 0.6 | 4,782 | Common Stock |
| Athira Pharma Inc | Mark Worthington | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.55 per share. | 31 Dec 2024 | 3,651 | 55,578 | - | 0.5 | 2,008 | Common Stock |
| Athira Pharma Inc | Mark Worthington | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 110,000 | 110,000 | - | - | Restricted Stock Units | |
| Athira Pharma Inc | Mark Worthington | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark Worthington | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 1.34 per share. | 03 Sep 2024 | 10,000 | 44,452 | - | 1.3 | 13,400 | Common Stock |
| Athira Pharma Inc | Mark Worthington | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 10,000 | 54,452 | - | 0 | Common Stock | |
| Athira Pharma Inc | Mark Worthington | GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 03 Sep 2024 | 2,525 | 51,927 | - | 0.6 | 1,429 | Common Stock |
| Athira Pharma Inc | Mark Worthington | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 220,000 | 220,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Worthington Mark | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 10,000 | 36,864 | - | 0 | Common Stock | |
| Athira Pharma Inc | Mark Worthington | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 10,000 | 36,864 | - | 0 | Common Stock | |
| Athira Pharma Inc | Worthington Mark | General Counsel | Grant, award, or other acquisition of securities at price $ 2.41 per share. | 04 Jan 2024 | 7,767 | 26,864 | - | 2.4 | 18,718 | Common Stock |
| Athira Pharma Inc | Worthington Mark | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 2.41 per share. | 04 Jan 2024 | 7,767 | 26,864 | - | 2.4 | 18,718 | Common Stock |
| Athira Pharma Inc | Mark Worthington | General Counsel | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 2,412 | 34,452 | - | 2.9 | 7,019 | Common Stock |
| Athira Pharma Inc | Worthington Mark | GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 2,412 | 34,452 | - | 2.9 | 7,019 | Common Stock |
| Athira Pharma Inc | Mark Worthington | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark Worthington | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges